This article is more than 5 years old. Information may no longer be current.
Ophthotech initiates phase 1 trial of anti-C5 aptamer for treating AMD
Click Here to Manage Email Alerts
PRINCETON, N.J. — Ophthotech has enrolled the first patient in a phase 1 clinical trial of ARC1905, an anti-C5 complement factor aptamer being developed to treat age-related macular degeneration, the company announced in a press release.
The study will evaluate the safety and tolerability of ARC1905 in combination with an anti-VEGF agent, the release said.
"Preclinical and human genetic linkage studies strongly support the significant role of complement-mediated inflammation in both dry and wet AMD," Samir Patel, MD, president and chief executive officer of Ophthotech, said in the release. "We believe that anti-C5 aptamer blockade represents a potential breakthrough therapy for both wet and dry forms of AMD."
ARC1905 is the second of three compounds — the others are E10030 and volociximab (M200) — that Ophthotech is developing to treat AMD.